terelilizumab

Terelilizumab (TQB3455) is a humanized monoclonal antibody designed to target the programmed cell death protein 1 (PD-1) receptor. Developed by Chia Tai Tianqing Pharmaceutical Group, it acts as an immune checkpoint inhibitor by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade prevents the inhibitory signaling that typically suppresses T-cell activity, thereby restoring and enhancing the immune system's ability to recognize and attack malignant cells. Terelilizumab is primarily being investigated for the treatment of advanced malignancies, including non-small cell lung cancer (NSCLC) and classical Hodgkin lymphoma. Clinical development has involved significant collaboration with institutions such as the Affiliated Hospital of Xuzhou Medical University, which has served as a lead site for several of its clinical trials.

Other names

terellizumab